BioScrip, Inc. (NASDAQ:BIOS) is set to release its earnings data before the market opens on Monday, November 6th. Analysts expect BioScrip to post earnings of ($0.10) per share for the quarter.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). The firm had revenue of $218.11 million for the quarter, compared to analyst estimates of $220.05 million. The company’s revenue was down 6.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.14) earnings per share. On average, analysts expect BioScrip to post $-0.55 EPS for the current fiscal year and $-0.17 EPS for the next fiscal year.

Shares of BioScrip, Inc. (NASDAQ:BIOS) opened at 2.51 on Monday. BioScrip, Inc. has a 52-week low of $0.98 and a 52-week high of $3.39. The stock’s 50 day moving average is $2.63 and its 200 day moving average is $2.44. The stock’s market capitalization is $319.96 million.

In other news, Director Coliseum Capital Management, L sold 2,846,941 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $2.93, for a total value of $8,341,537.13. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Michael G. Bronfein sold 27,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $2.69, for a total transaction of $72,630.00. Following the completion of the transaction, the director now owns 129,669 shares in the company, valued at $348,809.61. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,760,419 shares of company stock valued at $11,144,519. 0.80% of the stock is owned by company insiders.

A number of equities research analysts recently weighed in on BIOS shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $4.00 price target (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. ValuEngine lowered shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BidaskClub lowered shares of BioScrip from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 1st. Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a report on Wednesday, July 5th. Finally, SunTrust Banks, Inc. raised shares of BioScrip from a “hold” rating to a “buy” rating and raised their price objective for the stock from $3.25 to $3.75 in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $3.75.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/30/bioscrip-inc-bios-scheduled-to-post-earnings-on-monday.html.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Earnings History for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.